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Purpose: This study was conducted to evaluate the effectiveness and safety of intensity-modulated radiotherapy
(IMRT) and concurrent paclitaxel plus cisplatin (TP regimen) for upper esophageal carcinoma.
Methods: 36 patients of upper esophageal carcinoma were retrospectively analyzed. Patients were treated with
IMRT (median 60 Gy) combined with concurrent TP regimen chemotherapy. The Kaplan-Meier analysis was
performed in statistical analysis. Toxicities were recorded according to the NCI CTC version 3.0.
Results: 36 patients aged 43–73 years (median 57 years). The median follow-up period was 14.0 months. The 1-year
and 2-year survival rates were 83.3% and 42.8% respectively. The median progression-free survival (PFS) time and
overall survival (OS) time were 12.0 (95% CI: 7.8–16.2 months) and 18.0 months (95% CI: 9.9–26.1 months),
respectively. Grade 3 neutropenia, radiation-induced esophagitis and radiodermatitis were observed in 5 (13.9%),
3 (8.3%) and 8 (22.2%) patients respectively. There were two treatment-related deaths due to esophageal
perforation and hemorrhea.
Conclusions: For those patients with upper esophageal carcinoma, IMRT combined with concurrent TP regimen
chemotherapy was an effective treatment. However, more attention should be paid to the occurrence of
perforation and hemorrhea.
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The incidence of esophageal carcinoma is increasing
in the world as well as China. About 462,000 cases of
newly esophageal carcinoma were diagnosed worldwide
every year. It is the sixth leading cause of death from can-
cer, and the overall 5-year survival rate is only 10% [1,2].
Upper esophageal carcinoma, including cervical and upper
thoracic region, is relatively uncommon and accounts for
only 5%–10% of all esophageal carcinomas [3]. However,
it has a poor prognosis, and the reported 3- and 5-year
survival rates with surgical resection range from 18% to
35.4% and from 12% to 33%, respectively [4].* Correspondence: gongyouling@gmail.com
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reproduction in any medium, provided the orSurgery remained the gold standard of curative treat-
ment for carcinoma of esophagus. However, carcinoma
of upper esophagus was difficult to be resected and
achieved a clear margin based on complicated anatomic
structure. Besides, surgical complication and mortality
rates were severe, and the 5-year survival rate after
surgery was only 14–16% [5,6]. Chiu et al. conducted a
prospective randomized trial to compare standard esoph-
agectomy with definitive chemo-radiotherapy (CRT) for pa-
tients with potentially resectable squamous cell carcinoma
of esophagus [7]. Two groups achieved a similar disease-
free survival (24 vs. 20 months) and overall survival (24 vs.
21 months). Therefore, the definitive radiochemotherapy is
generally considered as the standard treatment for upper
esophageal carcinoma.
Currently, the optimal therapeutic schedule of upper
esophageal carcinoma remains undetermined, althoughThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with radiotherapy was generally recognized as the initial
strategy. The regarding data on other chemotherapeutics
in patients of upper esophageal carcinoma has been
lacking. Paclitaxel, a new broad-spectrum cytotoxic anti-
neoplastic, has shown some promising responses against
a great many carcinomas. As a single agent, paclitaxel has
been shown to have a response rate of 32% in esophageal
cancer [8]. In addition, several Phase II studies have found
that paclitaxel-based regimens have significant activity in
patients with locally advanced and metastatic esophageal
cancer [9-11]. It had been also demonstrated in vitro that
paclitaxel had radioenhancing effects in some tumor cell
lines [12-14]. And the combination of paclitaxel and plat-
inum with concurrent radiotherapy really showed a good
response in patients with esophageal cancer [15,16].
It is a challenge to deal with the target conformity and
risk organ sparing with 3-dimentional conformal radio-
therapy (3D-CRT) in treating upper esophageal carcinoma.
Intensity-modulated radiation therapy (IMRT) represents a
fundamentally new approach to the planning and delivery
of radiation therapy. It combines two advanced concepts
to deliver 3D-CRT: inverse treatment planning with
computerized optimization and computer-controlled in-
tensity modulation of the treatment beams, demonstrat-
ing the dosimetric superiority over 3D-CRT approaches
in nearly all of the major tumor sites.
So far, a few studies reported the concurrent CRT for
upper esophageal carcinoma [17-19], and the chemother-
apy they applied was the 5-FU based regimen. To our
knowledge, no data had been reported regarding to the
combination of TP regimen and IMRT technique. Thus
we conducted a retrospective study to evaluate the effect-
iveness and safety of IMRT and concurrent TP regimen
for upper esophageal carcinoma.Patients and methods
Patients’ data
From August 2006 to November 2011, all patients of
upper esophageal carcinoma treated with concurrent
chemoradiotherapy without surgery in West China Hos-
pital were retrospectively analyzed. To be included in
our analysis, patients needed to meet the following cri-
teria: All patients had a histologically proven esophageal
carcinoma; tumor was located in the cervical or thoracic
upper esophagus without visceral metastasis by esoph-
agogastroduodenoscopy, esophagography and computed
tomography (CT scan) at the time of diagnosis; they
were firstly treated with IMRT and concurrent TP regi-
men without surgery. Besides, we excluded patients if
they had treatment with radiotherapy alone, unaccom-
plished radiotherapy, recurrent disease, or the other
tumors in middle or lower esophagus.Tumor evaluation
Tumor evaluation was based on esophagogastroduode-
noscopy, esophagography, neck/chest/abdominal CT,
and endoscopic ultrasound of the esophagus. Tumor
baseline characteristics (TNM stage, location, size, and
histopathology) were taken. The tumor staging was
based on the 2002 American Joint Committee on Can-
cer (AJCC) staging system [20]. The tumor length was
defined by esophagogastroduodenoscopy or/and barium
esophagography and tumor diameter by CT scan. The
upper esophageal carcinoma was located in esophagus
above tracheal eminence, and 24 cm from incisor tooth
by esophagogastroduodenoscopy.
IMRT
Each patient was immobilized in the supine position.
The planning CT scans were performed at 3 mm slice
thickness using a dedicated helical CT scanner (Siemens,
Somatom Plus4) throughout the entire neck and thorax.
All of the CT images of patients acquired were transferred
to and registered in the treatment planning system (TPS)
with the same method. The gross tumor volume (GTV)
included all macroscopic tumors and enlarged lymph nodes
as determined by the imaging and endoscopic findings. The
clinical target volume (CTV) was defined as the GTV plus
a 2–3 cm radial margin. If the target was contoured in the
supraclavicular region, the correlated lymphatic drainage
region was contoured as the CTV, extending to the crico-
thyroid membrane. The planning target volume (PTV) was
defined as the CTV plus a 0.5 cm margin in all direction,
respectively. The median irradiation dose for the PTV was
60 Gy, with a range of 52–70 Gy at 1.8–2.0 Gy per fraction
and 5 fractions per week. The prescription dose covered at
least 95% of the volume of the PTV and the hot point was
limited within the 107% of the prescription dose. The dose
constraint for the spinal cord was a maximum dose <
45 Gy. For lungs, the mean dose and V20 were limited
within 15 Gy and 30% respectively. The IMRT plans were
generated using 5 or 7 co-planar beams with a 6-MV linear
accelerator.
Chemotherapy
The concurrent chemotherapy regimen started at the first
day of radiotherapy. The regimens consisted of paclitaxel
135 mg/m2 and DDP 75 mg/m2 on day one per 3 weeks. If
the grade 3 or higher treatment-related esophagitis were
found and lasting, the chemotherapy would be suspended
until recovery and reduced sequentially the regimen dose
by 25% in the subsequent cycle. All toxicities related to the
treatment were evaluated using the National Cancer Insti-
tute Common Toxicity Criteria (NCI CTC, version 3.0).
If grade 3 or higher side-effects were observed, the nu-
tritive sucking during gavage feedings and symptomatic
management was added during the treatment.
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Evaluation of treatment response was carried out according
to Response Evaluation Criteria in Solid Tumors (RECIST
criteria) [21]. The evaluation was performed 1 month after
CRT completion. The follow-up was performed on a
clinical basis, with barium esophagography and chest
and abdominal CT scans every 3 months for first year
and every 6 months thereafter. Follow-up data were
updated in May 2012.
Statistical analysis
Overall survival (OS) was calculated from the date of
CRT initiation until the date of death or the date of last
follow-up. Survival curve was established using Kaplan-
Meier method. Progression-free survival (PFS) was esti-
mated from the date of the first day of CRT initiation
to the time of documented failure (local recurrence or
metastasis occurrence) or the date of the last follow-
up for those remaining with CCR. A value of p < 0.05
(2-sided) was considered with statistical significance.
Statistical analysis was performed using SPSS 13.0 software.
Results
As shown in Table 1, 36 patients were evaluated in this
analysis. All cases were squamous cell carcinoma. The
median follow-up periods for 31 patients was 14.0 months
(range: 5.0- 65.0 months), 5 cases (13.9%) had been lostTable 1 Clinical characteristics of the patients (n = 36)
Characteristics Number of patients (%)
Age (years)
Median (range) 57 (43–73)
< 65 years 27 (75)
> 65 years 9 (25)
Gender





Cervical esophagus 4 (5.6)
Upper thoracic esophagus 32 (94.4)
Tumor length
< 5 cm 16 (44.4)
> 5 cm 20 (55.6)
Clinical tumorstageb
II stage 11 (30.6)
III stage 13 (36.1)
IV stage 12 (33.3)
a: Eastern Cooperative Oncology Group; b: Staging system, 6th edition,
American Joint Committee on Cancer, 2002.to follow-up. All patients completed the radiotherapy
treatment. 83.3% (30/36) patients had received 2 cycles
of TP chemotherapy, while the remaining patients had
received at least 1 cycle of chemotherapy.
Responses to treatment
All patients were assessed as having had a response
(Table 2). 6 (16.7%), 12 (33.3%) and 15 (41.7%) patients
showed complete response (CR), partial response (PR)
and stable disease (SD), respectively. The overall re-
sponses were 50% (18/36).
Follow-up
Follow-up studies continued until May 2012, with 5 pa-
tients lost to follow-up. The 1-year and 2-year survival
rates were 83.3% and 42.8% respectively. The median PFS
of all patients was 12.0 months (95% CI: 7.8–16.2 months)
(Figure 1) and the median OS was 18.0 months (95% CI:
9.9–26.1 months) (Figure 2).
Treatment-related toxicities
All the patients were evaluated for tretment-related toxic-
ities (Table 3). The combination of IMRT and TP regi-
mens were proved to be tolerable. The most common
hematologic toxicity was neutropenia. Grade 3 neutro-
penia were observed in 5 (13.9%) patients. The non-
hematological toxicities were generally found, but serious
cases were relatively few. Grade 3 digestive tract side-
effects, radiation esophagitis and radiodermatitis were
observed in 4 patients (11.1%), 3 patients (8.3%) and 8
patients (22.2%) respectively. Nevertheless, it was import-
ant to note that two patients experienced treatment-
related deaths for esophageal perforation and hemorrhea
one month after CRT.
Discussion
In this study, for the first time, IMRT and concurrent TP
regimen was demonstrated in patients of upper esopha-
geal cancer, and had shown a promising activity. Our
data showed that this strategy for patients with upper
esophageal cancer produced clinical outcome, which
was not worse than those results previously reported in
esophageal cancer.
The concurrent CRT has been increasedly used as pri-
mary therapy regimen in patients who had unresectable
esophageal carcinoma, were unwilling to undergo sur-
gery, or were medically unfit for surgery. The RTOG
85–01 trial firstly analyzed the efficacy of CRT as a de-
finitive treatment and revealed the superiority of CRT
over radiotherapy alone in regards to 5-years overall sur-
vival [22]. Furthermore, Wong et al. [23] found that
concomitant CRT is better than sequential CRT when a
non-operative approach is selected for patients with
localized esophageal cancer by meta-analysis. On these
Table 2 Response to treatment
Complete response (CR) Partial response (PR) Stable disease (SD) Progression disease (PD)
TP + R 6 (16.7%) 12 (33.3%) 15 (41.7%) 3 (8.3%)
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ies strategies to prolong the survival and improve patient’s
quality of life. A landmark study (INT 0123) found that
combined-modality therapy consisting of 5-FU and
DDP with concurrent 64.8 Gy was not better than the
same regimen with concurrent 50.4 Gy in survival (13.0
vs. 18.1 months) and local/regional control (56% vs.
52%) [24]. In an attempt to improve these results, the
RTOG 0113 phase II trial was designed to compare two
different chemotherapy regimen including 5-FU, DDP
and paclitaxel with concurrent 50.4 Gy of radiation in
patients with localized esophageal cancer [25]. Although
5-FU-based group seems better than non-5-FU-based
group and the result of INT 0123 study, it did not
achieve the desired 1-year survival mark. Also, the two
groups have 80% rate of grade 3 or 4 toxicities.
Treatment-related death occurred in 3% and 6% of pa-
tients in two arms relatively. Therefore, neither of the
two kinds of CRT strategies consisting of paclitaxel plus
DDP proved to be sufficiently superior to the historical
control of INT 0123 and warranted further investigation.
In our study, the median OS was 18.0 months, which was
relative higher than the results reported in TP-based
group of the RTOG 0113 study (18 vs. 14.9 months). In
addition, the grade 3 or 4 toxicities in our study wereFigure 1 Analysis of progression-free survival (PFS) in the studied poobviously lower than it, although the rates of the
treatment-related death were similar (5.5% in our study
and 6% in RTOG 0113 study). The reasons why this
significant difference existed in two studies might be
summarized as following: 1. the dose and time of TP
regimen were different in two studies, and our regimen
seemed more moderate; 2. 66% (23/35) of the patients
in the TP-based CRT group of the 0113 trial were
dignosed with the adenocarcinoma, while our patients
were all squamous-cell esophageal carcinoma. The dif-
ferent pathological types might result in different re-
sponse to CRT and the survival. However, our response
rate was relatively low especially for CR rate when com-
pared to those data reported previously. The possible
reason might be the different chemotherapy schedule.
In the previous studies, TP regimens were all scheduled
weekly while ours was 3-week based plan. Moreover,
surgery was performed in these studies that might have
an impact on the results as well.
Most reported literatures about CRT of upper esopha-
geal carcinoma have explored various combined-modality
therapeutic schedules. Wang et al. reported significant
results from a single institution experience of concur-
rent chemoradiation in 35 patients of cervical and upper
thoracic esophageal cancer [17]. Median radiation dosepulation.
Figure 2 Analysis of overall survival (OS) in the studied population.
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based. After a median follow-up of 39 months, the
median PFS was 6 months and OS was 13 months. In
addition, they showed that patients who received a ra-
diation dose of greater than or equal to 50 Gy had a
better outcome than those who received less than
50 Gy. In a recent study [18], the OS for patients in
the up-front chemoradiation group was 24.9 months
and the 2-year survival rate was 46.9%. The overall
survival was very good probably because surgery followed
CRT in 6 of 21 patients. Huang et al. reported their study
compared the results of CRT based on 5-FU and either
mitomycin C or DDP with 54 Gy of radiation with the
high-dose DDP and 70 Gy of conformal radiation [19].Table 3 Treatment-related toxicities
Toxicities Toxicity grades, n (%)
Grade 1 Grade 2 Grade 3
Hematological
Neutropenia 12(33.3) 8(22.2) 5(13.9)
Anemia 13(36.1) 5(13.9) 3(8.3)
Thrombocytopenia 10(27.8) 3(8.3) 3(8.3)
Non-hematological
Digestive tract side-effectsa 12(33.3) 5(13.9) 4(11.1)
Radiation esophagitis 7(19.4) 23(63.9) 3(8.3)
Radiodermatitis 3(8.3) 25(69.4) 8(22.2)
a: including nausea, vomiting and diarrhea.For all patients, the OS rate at 2 and 5 years were 46%
and 28% in these patients treated curatively, respectively.
However, no survival improvement could be showed after
changing the treatment policy to high-dose cisplatin based
and conventionally fractionated conformal radiotherapy.
To our knowledge, there were two studies investigated
the TP regimen combining the conformal radiotherapy
for esophageal carcinoma [26,27]. Both of them reported
the weekly paclitaxel (intravenous infusion) and DDP with
concurrent radiotherapy for esophageal carcinoma, some
of these patients followed by surgery. Although the
regimens were different between their studies and ours
(3-week based), the outcomes still indicated that the
TP regimen combined with radiotherapy for esophageal
carcinoma was effective and tolerable.
In our study, all acute toxicities were tolerable (Table 3).
The most common treatment-related toxicities included
the radio-dermatitis and radiation-induced esophagitis.
We had not observed the late-phase toxicities (such as
pneumonitis, pleural effusion, and cardiac effusion), the
reason might be that only partial volume of the lungs
and heart had been irradiated during IMRT treatment.
But one issue should be addressed here. In our study,
two patients died because of esophageal perforation and
hemorrhea after CRT. As reported in the RTOG 0113
trial, the majority of late radiation toxicities were related
to esophageal injury [25]. We found that the huge ulcers
(diameter ≥ 2 cm) were showed in the lesions of two
patients. It seemed to suggest that those inevitable
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more attention in concurrent CRT for ulcerated carcin-
oma in practice.
In conclusion, our results showed that IMRT com-
bined with concurrent TP regimen chemotherapy could
be considered as an effective treatment with no signifi-
cant toxicity in those patients with upper esophageal
carcinoma. Currently, because all studies were small and
retrospective, more studies on larger population are re-
quired to determine the specific treatment approach in
upper esophageal carcinomas.
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